Business Support · Founded 1959 · www.ptlenterprise.com · BSE 509220 · NSE PTL LTD · ISIN INE034D01049
No Notes Added Yet
Business
PTL Enterprises Ltd. is primarily engaged in a unique business model revolving around asset leasing and diversified investments. Its core business involves leasing out its tyre manufacturing plant located in Kochi, Kerala, to Apollo Tyres Ltd. This long-standing lease agreement provides a significant portion of its stable, recurring revenue. Beyond this, PTL has diversified its operations to include healthcare services (through its investment in KIMSHEALTH Hospital, Kochi), modest wind power generation, and a portfolio of strategic investments in various listed and unlisted entities. Essentially, PTL generates income from lease rentals, healthcare operations, power sales, and returns from its investment portfolio.
Revenue Mix
While specific percentage breakdowns can fluctuate, PTL's revenue streams primarily originate from:
Lease Rentals: The most significant and stable component, derived from the long-term lease of its tyre manufacturing plant to Apollo Tyres Ltd.
Healthcare Services: Revenue from the operation of hospitals, primarily KIMSHEALTH Hospital in Kochi, through an associate company. This segment has been growing and represents a substantial portion outside of lease rentals.
Power Generation: Minor revenue from the generation and sale of wind power.
Investment Income: Returns, dividends, and capital gains from its diverse investment portfolio.
The lease rentals from Apollo Tyres typically form the largest and most predictable part of its income.
Industry
PTL operates in a multi-faceted manner rather than a single industry.
Asset Leasing (Tyre Plant): In this unique niche, PTL acts as a landlord for a major industrial asset. It doesn't directly compete in tyre manufacturing but benefits from the stability of its tenant, Apollo Tyres.
Healthcare: Through its associate, PTL is positioned within the competitive Indian healthcare sector, specifically in the tertiary care segment in Kerala. It competes with other regional and national hospital chains.
Investments: It operates as an investment holding company to some extent, competing with other institutional or individual investors.
Its positioning is somewhat unique due to the stable base provided by the Apollo Tyres lease, allowing it to explore and diversify into other capital-intensive sectors like healthcare.
MOAT
PTL's primary competitive advantage or "moat" stems from:
Long-Term Lease Agreement: The established and long-standing lease agreement with Apollo Tyres Ltd. for its manufacturing plant provides a highly stable and predictable stream of recurring revenue. This contractual arrangement reduces operational risk associated with manufacturing and market fluctuations.
Diversified Asset Base: The diversification into healthcare and a strategic investment portfolio provides multiple streams of income, mitigating over-reliance on a single asset or industry, though the lease income remains dominant.
Brand and Management (Healthcare): In the healthcare segment, KIMSHEALTH has established a regional brand presence and reputation in Kerala, which can create patient loyalty and trust.
Growth Drivers
Growth in Healthcare Services: Expansion of KIMSHEALTH Hospital's operations, increase in patient footfall, and potential addition of new facilities or specialized services. The growing demand for quality healthcare in India supports this segment.
Performance of Investment Portfolio: Strategic investments in other businesses, if successful, can lead to capital appreciation and higher dividend income.
Lease Renewal Terms: While a stable income, future renegotiations or renewals of the Apollo Tyres lease agreement could potentially lead to revised (upward) rental terms, providing a boost to income.
Operational Efficiency: Improving efficiency in its diversified segments, particularly healthcare, can drive profitability.
Risks
Dependence on Apollo Tyres Lease: A significant portion of PTL's revenue is derived from the lease agreement with Apollo Tyres. Any adverse changes to this agreement, the financial health of Apollo Tyres, or the eventual terms of its renewal could significantly impact PTL's financials.
Healthcare Sector Risks: The healthcare industry is highly competitive, capital-intensive, and subject to regulatory changes, pricing pressures, and the need for continuous technological upgrades. Operational challenges or economic downturns affecting healthcare spending could impact profitability.
Investment Volatility: The performance of PTL's investment portfolio is subject to market risks, economic cycles, and the specific performance of the underlying companies, leading to potential fluctuations in asset values and returns.
Regulatory Risks: Changes in government policies, healthcare regulations, environmental norms, or corporate governance standards in India could affect its operations across segments.
Management & Ownership
PTL Enterprises Ltd. has a history intertwined with the larger Indian tyre industry, with past associations involving key figures in this sector. The company's promoters, as reported in public filings, typically hold a significant stake, demonstrating alignment with shareholder interests. Management quality is generally seen as stable, focusing on maintaining the core lease income and strategically diversifying into growing sectors like healthcare. The ownership structure includes promoter holding, institutional investors, and public shareholders, typical for a listed Indian company.
Outlook
PTL Enterprises presents a unique investment profile characterized by a stable base and diversification efforts. The primary bull case rests on the consistent, predictable cash flow from its long-term lease agreement with Apollo Tyres, which provides a strong foundation. This stability allows the company to strategically invest and grow its healthcare segment, which benefits from robust demand in India. Successful expansion and operational efficiency in KIMSHEALTH, coupled with prudent management of its investment portfolio, could unlock further value and drive earnings growth.
Conversely, the bear case highlights the significant dependence on the Apollo Tyres lease – any disruption or unfavorable renegotiation of this agreement could severely impact the company. The healthcare sector, while promising, is highly competitive and capital-intensive, requiring sustained investment and skilled management to navigate. Economic downturns, increased competition in healthcare, and volatility in its investment portfolio also pose risks. Overall, PTL offers a blend of stability from its legacy asset and potential upside from its diversified ventures, but with inherent risks tied to sector-specific challenges and its core contractual arrangement.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Other Income | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 6 | 0 | 4 |
| Total Income | 16 | 16 | 16 | 23 | 16 | 16 | 16 | 22 | 16 | 20 |
| Total Expenditure | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 2 | 1 |
| Operating Profit | 15 | 15 | 15 | 21 | 15 | 15 | 15 | 20 | 15 | 19 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 13 | 13 | 13 | 19 | 13 | 13 | 13 | 19 | 13 | 17 |
| Provision for Tax | 7 | 8 | 8 | 5 | 4 | 4 | 4 | 4 | 4 | 4 |
| Profit After Tax | 5 | 6 | 5 | 14 | 8 | 9 | 9 | 15 | 9 | 13 |
| Adjustments | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 5 | 6 | 5 | 14 | 8 | 9 | 9 | 15 | 9 | 13 |
| Adjusted Earnings Per Share | 0.4 | 0.4 | 0.4 | 1.1 | 0.6 | 0.7 | 0.7 | 1.1 | 0.7 | 1 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 40 | 46 | 53 | 60 | 63 | 63 | 63 | 63 | 64 | 64 | 64 | 64 |
| Other Income | 2 | 1 | 2 | 11 | 3 | 4 | 7 | 4 | 4 | 6 | 7 | 10 |
| Total Income | 42 | 47 | 56 | 71 | 66 | 67 | 71 | 67 | 69 | 70 | 71 | 74 |
| Total Expenditure | 9 | 4 | 5 | 4 | 5 | 5 | 6 | 6 | 6 | 8 | 6 | 5 |
| Operating Profit | 32 | 43 | 51 | 68 | 61 | 61 | 65 | 61 | 62 | 61 | 65 | 69 |
| Interest | 8 | 5 | 3 | 6 | 2 | 2 | 7 | 7 | 7 | 6 | 5 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 4 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 29 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 23 | 38 | 47 | 61 | 58 | 58 | 86 | 52 | 53 | 54 | 58 | 62 |
| Provision for Tax | 8 | 13 | 16 | 15 | 18 | 14 | 15 | 19 | 30 | 30 | 22 | 16 |
| Profit After Tax | 15 | 24 | 30 | 46 | 40 | 44 | 70 | 33 | 23 | 24 | 36 | 46 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 15 | 24 | 30 | 46 | 40 | 44 | 70 | 33 | 23 | 24 | 36 | 46 |
| Adjusted Earnings Per Share | 1.1 | 1.8 | 2.3 | 3.5 | 3 | 3.3 | 5.3 | 2.5 | 1.8 | 1.8 | 2.7 | 3.5 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 0% | 1% | 0% | 5% |
| Operating Profit CAGR | 7% | 2% | 1% | 7% |
| PAT CAGR | 50% | 3% | -4% | 9% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -6% | 7% | 11% | -4% |
| ROE Average | 7% | 6% | 12% | 19% |
| ROCE Average | 11% | 13% | 19% | 27% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 88 | 681 | 436 | 472 | 488 | 447 | 595 | 583 | 700 | 843 | 851 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 30 | 0 | 0 | 0 | 0 | 0 | 45 | 43 | 21 | 13 | 5 |
| Other Non-Current Liabilities | 53 | 63 | 176 | 185 | 325 | 336 | 364 | 361 | 210 | 226 | 190 |
| Total Current Liabilities | 117 | 118 | 125 | 14 | 17 | 19 | 23 | 23 | 243 | 274 | 291 |
| Total Liabilities | 288 | 861 | 737 | 670 | 830 | 802 | 1027 | 1011 | 1173 | 1357 | 1336 |
| Fixed Assets | 16 | 593 | 599 | 595 | 594 | 600 | 610 | 612 | 612 | 610 | 608 |
| Other Non-Current Assets | 180 | 164 | 1 | 57 | 234 | 197 | 366 | 377 | 345 | 503 | 459 |
| Total Current Assets | 92 | 104 | 137 | 19 | 2 | 5 | 52 | 21 | 216 | 244 | 269 |
| Total Assets | 288 | 861 | 737 | 670 | 830 | 802 | 1027 | 1011 | 1173 | 1357 | 1336 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 2 | 3 | 1 | 15 | 17 | 1 | 0 | 0 | 6 | 1 | 1 |
| Cash Flow from Operating Activities | 26 | 65 | 25 | 48 | 42 | 46 | 40 | 41 | 43 | 21 | 26 |
| Cash Flow from Investing Activities | 0 | -5 | -6 | -35 | -43 | -7 | -68 | -14 | 4 | 11 | 7 |
| Cash Flow from Financing Activities | -26 | -62 | -5 | -10 | -16 | -40 | 28 | -20 | -52 | -33 | -33 |
| Net Cash Inflow / Outflow | 0 | -2 | 14 | 2 | -17 | -0 | -0 | 6 | -5 | -0 | 0 |
| Closing Cash & Cash Equivalent | 3 | 1 | 15 | 17 | 1 | 0 | 0 | 6 | 1 | 1 | 1 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 1.14 | 1.83 | 2.29 | 3.46 | 3.01 | 3.32 | 5.29 | 2.49 | 1.76 | 1.78 | 2.74 |
| CEPS(Rs) | 1.21 | 1.88 | 2.36 | 3.55 | 3.1 | 3.41 | 5.41 | 2.63 | 1.91 | 1.94 | 2.9 |
| DPS(Rs) | 0.5 | 0.5 | 0.63 | 1 | 1.25 | 1.25 | 2.5 | 2 | 1.75 | 1.75 | 1.75 |
| Book NAV/Share(Rs) | 6.67 | 7.9 | 10.58 | 13.4 | 14.6 | 11.51 | 22.7 | 21.72 | 30.55 | 41.37 | 41.96 |
| Core EBITDA Margin(%) | 76.64 | 91.33 | 90.61 | 94.08 | 92.51 | 91.43 | 90.86 | 90.11 | 90.03 | 86.87 | 90.63 |
| EBIT Margin(%) | 78.17 | 92.98 | 92.84 | 110.7 | 95.19 | 95.09 | 146.42 | 93.89 | 93.35 | 92.26 | 97.9 |
| Pre Tax Margin(%) | 58.09 | 82.06 | 87.27 | 100.51 | 92.16 | 91.74 | 135.28 | 82.33 | 82.9 | 83.4 | 89.89 |
| PAT Margin (%) | 37.62 | 52.88 | 56.65 | 76.05 | 63.04 | 69.49 | 110.79 | 52.18 | 36.18 | 36.61 | 56.41 |
| Cash Profit Margin (%) | 39.92 | 54.29 | 58.41 | 78.02 | 64.96 | 71.46 | 113.33 | 55.04 | 39.37 | 39.87 | 59.65 |
| ROA(%) | 5.31 | 4.22 | 3.79 | 6.51 | 5.31 | 5.38 | 7.66 | 3.24 | 2.13 | 1.86 | 2.7 |
| ROE(%) | 17.75 | 25.13 | 24.77 | 28.88 | 21.51 | 25.42 | 30.93 | 11.22 | 6.73 | 4.95 | 6.58 |
| ROCE(%) | 22.53 | 35.27 | 40.59 | 42.04 | 32.48 | 34.79 | 36.95 | 17.32 | 15.61 | 11.86 | 11.07 |
| Receivable days | 1.38 | 0.66 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory Days | 0.5 | 0.44 | 0.38 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Payable days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PER(x) | 14.91 | 37.17 | 10.67 | 6.72 | 6.92 | 4.2 | 3.67 | 13.32 | 17.3 | 21.94 | 13.68 |
| Price/Book(x) | 2.54 | 8.61 | 2.31 | 1.74 | 1.43 | 1.21 | 0.85 | 1.53 | 1 | 0.94 | 0.89 |
| Dividend Yield(%) | 2.95 | 0.73 | 2.56 | 4.3 | 6 | 8.98 | 12.89 | 6.02 | 5.75 | 4.48 | 4.67 |
| EV/Net Sales(x) | 6.72 | 19.6 | 5.74 | 4.81 | 4.34 | 2.85 | 4.11 | 7.41 | 6.57 | 8.33 | 7.89 |
| EV/Core EBITDA(x) | 8.35 | 20.77 | 6.07 | 4.27 | 4.46 | 2.93 | 4.01 | 7.66 | 6.8 | 8.72 | 7.8 |
| Net Sales Growth(%) | 0 | 14.58 | 16.65 | 12.72 | 4.91 | 0.01 | -0.01 | 0 | 1.77 | 0.01 | -0.01 |
| EBIT Growth(%) | -12.94 | 36.29 | 16.48 | 34.39 | -9.79 | -0.1 | 53.96 | -35.87 | 1.19 | -1.16 | 6.1 |
| PAT Growth(%) | -14.58 | 61.08 | 24.97 | 51.32 | -13.05 | 10.24 | 59.43 | -52.9 | -29.44 | 1.22 | 54.05 |
| EPS Growth(%) | -14.58 | 61.08 | 24.97 | 51.32 | -13.05 | 10.24 | 59.43 | -52.9 | -29.44 | 1.22 | 54.05 |
| Debt/Equity(x) | 0.55 | 0 | 0 | 0 | 0 | 0 | 0.16 | 0.17 | 0.07 | 0.04 | 0.02 |
| Current Ratio(x) | 0.79 | 0.88 | 1.09 | 1.35 | 0.12 | 0.26 | 2.28 | 0.9 | 0.89 | 0.89 | 0.92 |
| Quick Ratio(x) | 0.79 | 0.88 | 1.09 | 1.35 | 0.12 | 0.26 | 2.28 | 0.9 | 0.89 | 0.89 | 0.92 |
| Interest Cover(x) | 3.89 | 8.52 | 16.66 | 10.87 | 31.37 | 28.36 | 13.15 | 8.12 | 8.93 | 10.41 | 12.23 |
| Total Debt/Mcap(x) | 0.22 | 0 | 0 | 0 | 0 | 0 | 0.19 | 0.11 | 0.07 | 0.04 | 0.03 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 69.82 | 69.82 | 69.82 | 69.82 | 69.82 | 69.82 | 69.82 | 69.82 | 69.82 | 69.82 |
| FII | 0.08 | 0 | 0.03 | 0.1 | 0 | 0 | 0.07 | 0 | 0 | 0 |
| DII | 8.27 | 8.27 | 8.27 | 8.27 | 8.27 | 8.27 | 8.27 | 8.27 | 8.27 | 8.27 |
| Public | 21.83 | 21.9 | 21.87 | 21.8 | 21.9 | 21.9 | 21.83 | 21.9 | 21.9 | 21.91 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 |
| FII | 0.01 | 0 | 0 | 0.01 | 0 | 0 | 0.01 | 0 | 0 | 0 |
| DII | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.09 |
| Public | 2.89 | 2.9 | 2.9 | 2.89 | 2.9 | 2.9 | 2.89 | 2.9 | 2.9 | 2.9 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13.24 | 13.24 | 13.24 | 13.24 | 13.24 | 13.24 | 13.24 | 13.24 | 13.24 | 13.24 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 0% | +1% | 0% | +5% |
| Operating Profit CAGR | +7% | +2% | +1% | +7% |
| PAT CAGR | +50% | +3% | -4% | +9% |
| Share Price CAGR | -6% | +7% | +11% | -4% |
| ROE Average | +7% | +6% | +12% | +19% |
| ROCE Average | +11% | +13% | +19% | +27% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 69.82 | 69.82 | 69.82 | 69.82 | 69.82 | 69.82 | 69.82 | 69.82 | 69.82 | 69.82 |
| FII | 0.08 | 0 | 0.03 | 0.1 | 0 | 0 | 0.07 | 0 | 0 | 0 |
| DII | 8.27 | 8.27 | 8.27 | 8.27 | 8.27 | 8.27 | 8.27 | 8.27 | 8.27 | 8.27 |
| Public | 30.18 | 30.18 | 30.18 | 30.18 | 30.18 | 30.18 | 30.18 | 30.18 | 30.18 | 30.18 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 |
| FII | 0.01 | 0 | 0 | 0.01 | 0 | 0 | 0.01 | 0 | 0 | 0 |
| DII | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.09 |
| Public | 3.99 | 3.99 | 3.99 | 3.99 | 3.99 | 3.99 | 3.99 | 3.99 | 3.99 | 3.99 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13.24 | 13.24 | 13.24 | 13.24 | 13.24 | 13.24 | 13.24 | 13.24 | 13.24 | 13.24 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.